{"id":"liposome-doxorubicin","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Mucositis"},{"rate":"30-50","effect":"Alopecia"},{"rate":"20-40","effect":"Palmar-plantar erythrodysesthesia (hand-foot syndrome)"},{"rate":"<5","effect":"Cardiotoxicity (reduced vs. free doxorubicin)"}]},"_chembl":null,"_dailymed":{"setId":"c8eb4784-36e0-483f-9e5d-af0552e49bb5","title":"DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [SAGENT PHARMACEUTICALS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxorubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA replication in rapidly dividing cells. By encapsulating doxorubicin in liposomes, the formulation preferentially accumulates in tumor tissues through the enhanced permeability and retention (EPR) effect, reducing cardiotoxicity and other systemic toxicities associated with free doxorubicin while maintaining anti-tumor efficacy.","oneSentence":"Liposome-encapsulated doxorubicin delivers the chemotherapy agent doxorubicin to cancer cells while reducing exposure to healthy tissues, thereby improving tolerability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:32.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Ovarian cancer"},{"name":"Multiple myeloma"},{"name":"Kaposi sarcoma"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT05610735","phase":"PHASE1, PHASE2","title":"Combination Therapy for Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Sham Sunder Kakar","startDate":"2024-09-25","conditions":"Recurrent Ovarian Cancer","enrollment":72},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT06072781","phase":"PHASE3","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2024-03-18","conditions":"Low Grade Serous Ovarian Cancer","enrollment":270},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":"Ovarian Cancer","enrollment":358},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06345950","phase":"NA","title":"Pharmacokinetics and Safety of a New Micellar Glutathione Formulation","status":"COMPLETED","sponsor":"Factors Group of Nutritional Companies Inc.","startDate":"2022-06-21","conditions":"Bioavailability Heathy Volunteers, Safety","enrollment":16},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT02659930","phase":"PHASE1","title":"Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-01-13","conditions":"Kaposi Sarcoma","enrollment":62},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT07125183","phase":"PHASE2","title":"Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-12","conditions":"Sarcoma","enrollment":20},{"nctId":"NCT04457089","phase":"EARLY_PHASE1","title":"Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer","status":"COMPLETED","sponsor":"Marc Goodman","startDate":"2021-01-25","conditions":"Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer","enrollment":18},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT06815497","phase":"PHASE2","title":"Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2026-01-21","conditions":"Ovarian Cancer","enrollment":33},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT05411237","phase":"PHASE3","title":"Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2026-09","conditions":"Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma","enrollment":130},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT06981637","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-12-31","conditions":"Advanced Soft Tissue Sarcoma","enrollment":81},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT06161025","phase":"PHASE2, PHASE3","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-27","conditions":"Solid Cancer","enrollment":860},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06849986","phase":"PHASE2","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-25","conditions":"Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma","enrollment":45},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT05483933","phase":"PHASE1","title":"Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers","status":"COMPLETED","sponsor":"Shattuck Labs, Inc.","startDate":"2022-08-18","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT07286240","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-11-15","conditions":"Treatment of Recurrent Ovarian Cancer","enrollment":40},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT03618550","phase":"PHASE2","title":"Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-01","conditions":"Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma","enrollment":257},{"nctId":"NCT07243626","phase":"PHASE2","title":"Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-30","conditions":"Soft Tissue Sarcoma","enrollment":15},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":"Lymphoma, Large B-Cell, Diffuse Large B-Cell","enrollment":127},{"nctId":"NCT05949021","phase":"PHASE2","title":"OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mridula George, MD","startDate":"2023-10-07","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":"B-cell Lymphoma, Burkitt Lymphoma","enrollment":11},{"nctId":"NCT05864534","phase":"PHASE2","title":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-01-31","conditions":"Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma","enrollment":25},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT02858999","phase":"PHASE2","title":"Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT04908787","phase":"PHASE3","title":"A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-06-11","conditions":"Ovarian Cancer","enrollment":421},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT04243616","phase":"PHASE2","title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-03-05","conditions":"Invasive Breast Cancer","enrollment":36},{"nctId":"NCT00911183","phase":"PHASE2","title":"Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-12-02","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT06994195","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-04","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":384},{"nctId":"NCT05029999","phase":"PHASE1","title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-04-20","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT07120217","phase":"","title":"Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.","status":"COMPLETED","sponsor":"Federico II University","startDate":"2008-01-01","conditions":"Hodgkin Disease, Breast Cancer, Liposomal Doxorubicin","enrollment":200},{"nctId":"NCT02734771","phase":"PHASE2","title":"A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Reagan","startDate":"2016-06","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT06611813","phase":"PHASE2","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-11","conditions":"HR+/HER2- Breast Cancer","enrollment":30},{"nctId":"NCT06356883","phase":"PHASE2","title":"Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-08","conditions":"Glioblastoma Multiforme, Relapse","enrollment":120},{"nctId":"NCT06876636","phase":"NA","title":"Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-03-10","conditions":"Breast Cancer Metastatic","enrollment":99},{"nctId":"NCT05858710","phase":"PHASE1","title":"Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Thermosome GmbH","startDate":"2023-04-19","conditions":"Sarcoma, Soft Tissue","enrollment":8},{"nctId":"NCT02911142","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-03","conditions":"Primary Effusion Lymphoma, B-Cell Neoplasm","enrollment":17},{"nctId":"NCT06914440","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-06-05","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":348},{"nctId":"NCT06023862","phase":"PHASE2","title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-01-22","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":198},{"nctId":"NCT06292286","phase":"NA","title":"Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-11-01","conditions":"Recurrent Ovarian Carcinoma","enrollment":18},{"nctId":"NCT05008224","phase":"PHASE2","title":"Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-10-07","conditions":"Classical Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT05567601","phase":"PHASE1","title":"Doxil/Caelyx BE Study","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2023-12-16","conditions":"Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma","enrollment":36},{"nctId":"NCT00945724","phase":"PHASE2","title":"Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-09-27","conditions":"Large B-cell Diffuse Lymphoma of Testis","enrollment":54},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT04575961","phase":"PHASE2","title":"Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2022-02-22","conditions":"Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma","enrollment":33},{"nctId":"NCT06977893","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-24","conditions":"HR+/HER2- Breast Cancer","enrollment":194},{"nctId":"NCT05830539","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-03-10","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":68},{"nctId":"NCT03971409","phase":"PHASE2","title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Laura Huppert, MD, BA","startDate":"2019-07-08","conditions":"Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":150},{"nctId":"NCT01818063","phase":"PHASE2","title":"Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-04-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":9},{"nctId":"NCT06014528","phase":"PHASE2","title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-09-06","conditions":"Ovarian Cancer Recurrent","enrollment":168},{"nctId":"NCT05457829","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-30","conditions":"Rhabdomyosarcoma, Child","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["liposome adriamycin","Caelyx"],"phase":"marketed","status":"active","brandName":"Liposome doxorubicin","genericName":"Liposome doxorubicin","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liposome-encapsulated doxorubicin delivers the chemotherapy agent doxorubicin to cancer cells while reducing exposure to healthy tissues, thereby improving tolerability. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}